Development of Poly(ɛ-caprolactone) Scaffold Loaded with Simvastatin and Beta-Cyclodextrin Modified Hydroxyapatite...

Area of Science:

• Biomaterials Science
• Tissue Engineering
• Drug Delivery Systems

Background:

• Poly(ɛ-caprolactone) (PCL) scaffolds are widely used in tissue engineering.
• Incorporating bioactive agents can improve scaffold functionality.
• Controlled drug release is crucial for enhancing cellular responses.

Purpose of the Study:

• To develop novel 3D scaffolds for enhanced osteogenic differentiation.
• To functionalize PCL scaffolds with β-cyclodextrin (βCD) grafted hydroxyapatite (HAp).
• To investigate the drug loading and release capabilities of the modified scaffolds.

Main Methods:

• Fabrication of PCL 3D scaffolds using solid free form fabrication (SFF).
• Grafting of βCD to HAp and subsequent coating onto PCL scaffolds.
• Drug loading of simvastatin (SIM) via inclusion complex formation with βCD.
• Characterization using scanning electron microscopy (SEM) and evaluation of SIM release profile.
• Assessment of osteogenic differentiation of adipose-derived stromal cells (ADSCs) using alkaline phosphatase activity (ALP) assay.

Main Results:

• Successful fabrication of βCD-grafted HAp coated PCL 3D scaffolds.
• Demonstrated drug loading and controlled release of simvastatin.
• Significant enhancement of osteogenic differentiation in ADSCs cultured on drug-loaded scaffolds.

Conclusions:

• The developed PCL-HAp-βCD 3D scaffolds effectively load and release simvastatin.
• These scaffolds promote osteogenic differentiation of ADSCs.
• This approach holds promise for bone tissue engineering applications.